Search
for
Sort by
Research 841–870 of 1000+
- Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Phase I Clinical Trial: Evaluating the Efficacy, Safety, and Patient Satisfaction of Platelet‐Rich Plasma (PRP) Injections and Microneedling for Androgenetic Alopecia Treatment
- 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials
- Phase-specific differential regulation of mechanical allodynia in a murine model of neuropathic pain by progesterone
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
- The effect of St. John’s wort treatment on finasteride pharmacokinetics and identification of new phase I and phase II metabolites in humans
- Phase I Clinical Testing Antimalarial Drugs.
- Progress of Phage Therapy for Acne Vulgaris
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
- A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
- Hair Cycle Resting Phase Is Regulated by Cyclic Epithelial FGF18 Signaling
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- PDGF isoforms induce and maintain anagen phase of murine hair follicles
- A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy
- Exogen, Shedding Phase of the Hair Growth Cycle: Characterization of a Mouse Model
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Thrombospondin-1 Plays a Critical Role in the Induction of Hair Follicle Involution and Vascular Regression During the Catagen Phase
- Lipid peroxides induce early onset of catagen phase in murine hair cycles
- De Novo Production of Dermal Papilla Cells during the Anagen Phase of the Hair Cycle
- Expression of Cyclooxygenase Isozymes During Morphogenesis and Cycling of Pelage Hair Follicles in Mouse Skin: Precocious Onset of the First Catagen Phase and Alopecia upon Cyclooxygenase-2 Overexpression
- Identification of microRNAs in Wool Follicles during Anagen, Catagen, and Telogen Phases in Tibetan Sheep
- First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
- STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
- Leptin of dermal adipose tissue is differentially expressed during the hair cycle and contributes to adipocyte‐mediated growth inhibition of anagen‐phase vibrissa hair
- Morus alba Root Extract Induces the Anagen Phase in the Human Hair Follicle Dermal Papilla Cells
- Adenosine stimulates growth of dermal papilla and lengthens the anagen phase by increasing the cysteine level via fibroblast growth factors 2 and 7 in an organ culture of mouse vibrissae hair follicles
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata